Innate Pharma‘s patent involves methods for treating peripheral T-cell lymphoma by targeting NKp46-expressing tumor cells. The patent also covers the use of anti-NKp46 antibodies for diagnosing and treating refractory celiac disease. GlobalData’s report on Innate Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Innate Pharma, Personalized cancer vaccines was a key innovation area identified from patents. Innate Pharma's grant share as of May 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment and diagnosis of peripheral t-cell lymphoma using nkp46
A recently granted patent (Publication Number: US11999784B2) discloses a method for detecting NKp46 expression in individuals with refractory celiac disease (RCD) and subsequently treating them. The method involves obtaining a biological sample containing RCD cells from the individual, then contacting these cells with an antibody that binds to the NKp46 polypeptide and detecting the expression of NKp46 on the cell surface. Individuals expressing NKp46 on RCD cells are then treated with anti-NKp46 antibodies.
This innovative method provides a targeted approach for detecting and treating refractory celiac disease by focusing on the expression of NKp46. By specifically targeting NKp46-expressing RCD cells with anti-NKp46 antibodies, this method offers a potential treatment option for individuals with this condition. Further research and clinical trials may be needed to validate the efficacy and safety of this approach in managing refractory celiac disease.
To know more about GlobalData’s detailed insights on Innate Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
